TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04975139

Intervention type: DEVICE
Intervention: RS-fMRI
Description: Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain

Intervention type: DEVICE
Intervention: RS-fMRI
Description: Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain

Intervention type: DEVICE
Intervention: RS-fMRI
Description: Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
Study: NCT03366272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: eight cycles of R-GemOx in 2-wk intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: eight cycles of R-GemOx in 2-wk intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: eight cycles of (R)-GemOx in 2-wk intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: eight cycles of (R)-GemOx in 2-wk intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: eight cycles of (R)-GemOx in 2-wk intervals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: eight cycles of (R)-GemOx in 2-wk intervals
Study: NCT04075292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: acalabrutinib 100 mg twice daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
Study: NCT02414477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated NNN
Description: Smokeless tobacco study product
Study: NCT03363087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping
Description: Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
Study: NCT02034682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte 6%
Description: During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geloplasma
Description: During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
Study: NCT00857831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium
Description: 2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
Study: NCT04641143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Troriluzole
Description: Troriluzole - 2 100mg capsules QD for the first two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo - 2 140mg capsules QD from week two through week ten.
Study: NCT03871010

Intervention type: DEVICE
Intervention: Midline catheter
Description: Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.

Intervention type: DEVICE
Intervention: Midline catheter
Description: Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.

Intervention type: DEVICE
Intervention: Midline catheter
Description: Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
Study: NCT04595435

Intervention type: PROCEDURE
Intervention: Lumpectomy
Description: Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.

Intervention type: PROCEDURE
Intervention: Lumpectomy
Description: Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.

Intervention type: RADIATION
Intervention: Intraoperative Radiation Therapy
Description: Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure

Intervention type: RADIATION
Intervention: Intraoperative Radiation Therapy
Description: Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
Study: NCT02324062

Intervention type: OTHER
Intervention: Blood Draw and Baseline Questionnaire
Description: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
Study: NCT04299490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Fragmentation
Description: Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
Description: On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
Study: NCT03485287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
Study: NCT04280029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ DEB
Description: The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: POBA or FDA-approved -limus DES
Study: NCT02116335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stress response and vascular function will be assessed 3 days following twice per day placebo
Study: NCT03485287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized therapy
Description: Non-directive therapy
Study: NCT05577624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral capsule
Study: NCT00499330

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lobectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: segmentectomy or wedge resection
Study: NCT04299490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
Description: On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
Description: On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
Study: NCT03958747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound - Serial and Tibial Nerve
Description: Participants will undergo a serial and tibial nerve ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abbreviated Neurologic Exam
Description: Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: 12 ml blood sample will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nerve Conduction Study
Description: Sural and tibial nerve assessments
Study: NCT03779984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Rubber Catheter
Description: Experimental group will be intubated with red rubber catheter guidance

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard nasal tracheal Intubation
Description: Control group will be intubated with standard nasal tracheal tube without guidance
Study: NCT03289039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, works in treating breast cancer that has spread to other parts of the body
Study: NCT03958747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLQ-CIPN20 Questionnaire Administration
Description: Self-reported neuropathy scoring questionnaire completed same day as blood draw.
Study: NCT06454825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous drug
Description: medications were applied intravenously to the groups 30 minutes before end of the procedure
Study: NCT04094519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: oral
Study: NCT06215547

Intervention type: DEVICE
Group type: OTHER
Intervention: Enterra HDE
Description: Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit
Study: NCT02972034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: PO capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: PO capsule
Study: NCT04299490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Continuity Disruption
Description: An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Undisturbed Sleep
Description: Subjects sleep normally for an 8 hour period.
Study: NCT03779724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Study: NCT02886520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVDF transobturator tape

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene transobturator tape
Study: NCT03266094

Intervention type: DEVICE
Group type: OTHER
Intervention: BiZact™: A bipolar instrument for tonsillectomies
Description: A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
Study: NCT03548909

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Immunodiagnostic Products
Description: NT-proBNP II assay

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Immunodiagnostic Products
Description: NT-proBNP II assay
Study: NCT01448278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: All-inside
Description: The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical technique
Description: The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
Study: NCT01850524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: IXAZOMIB capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IXAZOMIB matching-placebo capsules.
Study: NCT02972034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: PO capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: PO capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT06454825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous drug
Description: medications were applied intravenously to the groups 30 minutes before end of the procedure
Study: NCT04126070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
Study: NCT01696019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast walking
Description: Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
Study: NCT04126070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
Study: NCT01696019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intellectual stimulation
Description: Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contact and testing only
Study: NCT00006003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04261725

Intervention type: GENETIC
Intervention: EGFR mutation
Description: Searching the EGFR mutation in pulmonary biopsy
Study: NCT05321758

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Immunosuppressive Agents
Description: hormones, azathioprine, thalidomide
Study: NCT02552745

Intervention type: DRUG
Intervention: parecoxib sodium
Description: parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
Study: NCT02070419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization
Description: Undergo TACE with doxorubicin-eluting beads

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Description: Undergo TACE with doxorubicin-eluting beads

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo SBRT
Study: NCT04607213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advancement-rotation approach based on Millard' for repairing lip defect.
Description: patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight-line approach
Description: patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar.
Study: NCT00494650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief PTSD treatment
Description: Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.